Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An insight to the molecular interactions of the FDA approved HIV PR drugs against L38L↑N↑L PR mutant.

Journal of computer-aided molecular design - 1 Mar 2018

Sanusi Zainab K, Govender Thavendran, Maguire Glenn E M, Maseko Sibusiso B, Lin Johnson, Kruger Hendrik G, Honarparvar Bahareh

Abstract excerpt

The aspartate protease of the human immune deficiency type-1 virus (HIV-1) has become a crucial antiviral target in which many useful antiretroviral inhibitors have been developed. However, it seems the emergence of new HIV-1 PR mutations enhances drug resistance, hence, the available FDA approved drugs show less activity towards the protease. A mutation and insertion designated L38L↑N↑L PR was recently reported...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Approval

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Hydrogen Bonding

Share to Thermodynamics

Share to United States Food and Drug Administration

Source

Identifiers

PMID: 29397520
DOI: 10.1007/s10822-018-0099-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An insight to the molecular interactions of the FDA approved HIV PR drugs against L38L↑N↑L PR mutant.PMID 29397520Read ↗

Binding energy analysis for wild-type and Y181C mutant HIV-1 RT/8-Cl TIBO complex structures: quantum chemical calculations based on the ONIOM method.Semantic proximity Read ↗

An in silico pharmacological approach toward the discovery of potent inhibitors to combat drug resistance HIV‐1 protease variantsSemantic proximity Read ↗

Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations.Semantic proximity Read ↗

Insights into the interaction mechanism of first-generation HIV-1 protease inhibitors with wild-type and mutant (D30N and L76V) enzymes through in-silico based approach.Semantic proximity Read ↗

Multiple Molecular Dynamics Simulations and Free-Energy Predictions Uncover the Susceptibility of Variants of HIV-1 Protease against Inhibitors Darunavir and KNI-1657.Semantic proximity Read ↗

Computational study of the interaction between TIBO inhibitors and Y181 (C181), K101, and Y188 amino acids.Semantic proximity Read ↗

Predicting drug resistance of the HIV-1 protease using molecular interaction energy components.Semantic proximity Read ↗

Multiple Molecular Dynamics Simulations of the Inhibitor GRL-02031 Complex with Wild Type and Mutant HIV-1 Protease Reveal the Binding and Drug-Resistance Mechanism.Semantic proximity Read ↗

Consistent Prediction of Mutation Effect on Drug Binding in HIV-1 Protease Using Alchemical CalculationsSemantic proximity Read ↗

Computational Studies of a Mechanism for Binding and Drug Resistance in the Wild Type and Four Mutations of HIV-1 Protease with a GRL-0519 Inhibitor.Semantic proximity Read ↗

Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate.Semantic proximity Read ↗

Prediction and molecular field view of drug resistance in HIV-1 protease mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.